Systems Biology and Drug Screening

September 17, 2015
by Pharm Tao

Conventional drug design mostly uses the ligand and structure-based approaches (Prathipati and Mizuguchi, 2015). With the advancement in functional genomics and the availability of high-throughput (HTP) data, information on interactive molecular networks can be used to analyze the efficacy and toxicity of various drugs from a more comprehensive view.

High content screens with systems biology analyses may help detect the cellular changes in details (Dunn et al., 2010). Transcriptomic and proteomic profiling would enable the description of the cellular alterations related to diseases and drug responses. Libraries can be constructed for not only small molecules, but also the molecular pathways and networks to facilitate drug screening and design.

Novel systems biology methods based on multiple platforms and various sources with multi-dimensional analyses put emphasis on the cellular networks and relationships among potential drug components.

References:

Dunn DA, Apanovitch D, Follettie M, He T, Ryan T. Taking a systems approach to the identification of novel therapeutic targets and biomarkers. Curr Pharm Biotechnol. 2010 Nov;11(7):721-34.

Prathipati P, Mizuguchi K. Systems biology approaches to a rational drug discovery paradigm. Curr Top Med Chem. 2015 Aug 26.

Leave a Reply

Copyright © 2006-2017 PharmTao.com. All Rights Reserved.

Disclaimer: By using this site, the readers agree that the content on our web pages is for information purpose only. The information provided on our web pages is not intended for diagnosis, or to treat, cure or prevent any diseases, conditions or symptoms, or to endorse any products. Personal directions and the use of health products should be provided by qualified health professionals.

Mind-Body, Personalized, and Systems Medicine